ライフサイエンスコーパス: cost-effectiveness analysis

1 for type 2 diabetes should be established by cost-effectiveness analysis.

2 servative assumptions, the authors performed cost-effectiveness analysis.

3 oring) were derived from data in the GUSTO-1 cost-effectiveness analysis.

4 ths after hospitalization and (2) a lifetime cost-effectiveness analysis.

5 cal technologies, with a particular focus on cost-effectiveness analysis.

6 er importance on equity than is reflected by cost-effectiveness analysis.

7 We compared alternatives using incremental cost-effectiveness analysis.

8 This study omitted cost-effectiveness analysis.

9 rmatics, 3) databases, 4) biomarkers, and 5) cost-effectiveness analysis.

10 randomised controlled trial with a parallel cost-effectiveness analysis.

11 r error avoided was estimated by incremental cost-effectiveness analysis.

12 We did a Markov model-based probabilistic cost-effectiveness analysis.

13 es a conceptual link with the denominator of cost-effectiveness analysis.

14 have implications for decision analysis and cost-effectiveness analysis.

15 Model-based cost-effectiveness analysis.

16 's recommendations define a "reference case" cost-effectiveness analysis, a standard set of methods t

17 We did a cost-effectiveness analysis alongside a cluster-randomis

18 ion analysis; (2) cost-benefit analysis; (3) cost-effectiveness analysis and (4) cost-utility analysi

19 reviewed the current status of the field of cost-effectiveness analysis and developed a new set of r

20 ion analysis, (2) cost-benefit analysis, (3) cost-effectiveness analysis, and (4) cost-utility analys

21 96, researchers have advanced the methods of cost-effectiveness analysis, and policy makers have expe

22 , budget impact, and sustainability into the cost-effectiveness analysis are needed to reach this goa

23 s the rationale, terminology, and methods of cost-effectiveness analysis as applied to radiology.

24 A cost-effectiveness analysis based on probabilities of ch

25 to be based not only on outcome evidence and cost-effectiveness analysis, but also on safety consider

26 care, abandoning the formulaic pretenses of cost-effectiveness analysis, but with a commitment to re

27 Cost-effectiveness analysis can be used to inform medica

28 Simulation models that support decision and cost-effectiveness analysis can further the goals of evi

29 Cost-effectiveness analysis can help to inform research

30 Cost-effectiveness analysis (CEA) compares the cost of t

31 Cost-effectiveness analysis (CEA) is a research method u

32 Cost-effectiveness analysis (CEA) is an analytic tool th

33 This cost-effectiveness analysis (CEA) provides important dat

34 Cost-effectiveness analysis (CEA) refers to a set of res

35 In cost-effectiveness analysis, choice for both age groups

36 A cost-effectiveness analysis compared the three arms of t

37 nd eliminated wait time (EWT), and perform a cost-effectiveness analysis comparing RWT and EWT with c

38 ts were combined with clinical outcomes in a cost-effectiveness analysis comparing the intervention w

39 The aim of this study was to conduct a cost-effectiveness analysis comparing TIPS with endoscop

40 Design, Setting, and Participants: This cost-effectiveness analysis conducted from September 201

41 Proper use of cost-effectiveness analysis could provide valuable evide

42 The cost effectiveness analysis did not indicate that the qu

43 The probabilistic cost-effectiveness analysis estimated an incremental cos

44 The base case cost-effectiveness analysis estimated telemedicine in th

45 We did a cost-effectiveness analysis for these strategies, implem

46 the Ministry of Health and Population, and a cost-effectiveness analysis, from a societal perspective

47 able to other cancer interventions for which cost-effectiveness analysis has been performed.

48 reatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted.

49 Guidelines based on systematic reviews and a cost-effectiveness analysis have suggested that it is wo

50 uld undergo imaging and, in combination with cost-effectiveness analysis, how imaging should be perfo

51 ragmatic randomized trial with an integrated cost-effectiveness analysis in 56 hospitals in England.

52 lower total positive rates yield a promising cost-effectiveness analysis in favor of universal ECG sc

53 to our knowledge there has been no previous cost-effectiveness analysis in pediatric IF including IR

54 d febrile neutropenia cost information and a cost-effectiveness analysis in the adjuvant breast cance

55 Cost-utility analysis is a type of cost-effectiveness analysis in which health effects are

56 Cost-effectiveness analysis is a state-of-the-art resear

57 Cost-effectiveness analysis is an objective method to es

58 Cost-effectiveness analysis is an objective systematic t

59 Cost-effectiveness analysis is often suggested as a mean

60 hen there are budget limitations, the use of cost-effectiveness analysis leads to health care policie

61 We use extended cost-effectiveness analysis methods to estimate, across

62 he proposed intervention and finally perform cost effectiveness analysis of the results.

63 We did a cost-effectiveness analysis of 43 insecticide-based vect

64 Decision and cost-effectiveness analysis of a strategy of full deploy

65 rpose of this investigation was to perform a cost-effectiveness analysis of adjunctive oral and intra

66 mplementation in South Africa we performed a cost-effectiveness analysis of alternative preventive st

67 We conducted a cost-effectiveness analysis of argatroban, bivalirudin,

68 We review the principles underlying cost-effectiveness analysis of diagnostic tests and proc

69 Comparative cost-effectiveness analysis of DSAEK versus PK indicates

70 We present a cost-effectiveness analysis of elective neck dissection

71 US adults (aged 15-65 years) and conducted a cost-effectiveness analysis of improvements along the HI

72 of treatment provide information for future cost-effectiveness analysis of potential innovative inte

73 The cost-effectiveness analysis of the Public Access Defibri

74 A cost-effectiveness analysis of the study results demonst

75 Perform a cost-effectiveness analysis of the treatment of diabetic

76 This article presents a cost-effectiveness analysis of these two treatment regim

77 ted thromboses, but confirmatory studies and cost-effectiveness analysis of this approach are needed.

78 y heart disease with lipid lowering therapy, cost effectiveness analysis offers an important tool to

79 m this review could be used to inform future cost-effectiveness analysis on the impact of LTBI screen

80 tiveness ratio" OR "economic evaluation" OR "cost effectiveness analysis" OR "cost utility analysis"

81 c malignancies from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.or

82 Cost-effectiveness analysis should include recognition t

83 familiar with the concepts and procedures of cost-effectiveness analysis so they can properly evaluat

84 eness analysis so they can properly evaluate cost-effectiveness analysis studies and be more knowledg

85 nt colonic obstruction has been supported by cost-effectiveness analysis studies and several pooled a

86 Our cost-effectiveness analysis suggests surveillance imagin

87 en unselected for hormone receptor status, a cost-effectiveness analysis suggests that this intervent

88 In a cost-effectiveness analysis, the average cost of total-b

89 In the cost-effectiveness analysis, the care bundle was estimat

90 For the purposes of clinical prognosis and cost-effectiveness analysis, the long-term survival of p

91 s in more detail the elements contained in a cost-effectiveness analysis, the preferred approach to p

92 For the cost-effectiveness analysis, the primary outcome was the

93 Extending the cost-effectiveness analysis to a seven-year base-case ti

94 We performed a cost-effectiveness analysis to assess diagnosis and trea

95 We conducted a cost-effectiveness analysis to assess the benefits of di

96 We used extended cost-effectiveness analysis to assess the health gains (

97 We performed a cost-effectiveness analysis to assess the value of addin

98 We performed a cost-effectiveness analysis to determine optimal CRC scr

99 We conducted a cost-effectiveness analysis to determine whether prophyl

100 eatment trials are warranted, we conducted a cost-effectiveness analysis to estimate the costs and be

101 This study's first aim was to conduct a cost-effectiveness analysis to estimate the incremental

102 rd trimesters, but noted the importance of a cost-effectiveness analysis to lend support to the decis

103 This article demonstrates the usefulness of cost-effectiveness analysis to support these decisions.

104 e, randomised controlled trial with parallel cost-effectiveness analysis undertaken in England, 701 a

105 Our base case cost-effectiveness analysis used empirical clinical and

106 A cost-effectiveness analysis using a Markov model from th

107 nts with atrial fibrillation, we performed a cost-effectiveness analysis using patient-level data fro

108 We did a within-trial cost-effectiveness analysis using person-level data and

109 A cost-effectiveness analysis was conducted using a Markov

110 A cost-effectiveness analysis was conducted.

111 Our base-case cost-effectiveness analysis was from the societal perspe

112 Cost-effectiveness analysis was limited by lack of prosp

113 This cost-effectiveness analysis was made from data from the

114 This cost-effectiveness analysis was performed from a third-p

115 The cost-effectiveness analysis was performed from the persp

116 A cost-effectiveness analysis was performed from the socie

117 lled trial with two open parallel arms and a cost-effectiveness analysis was performed in 12 tertiary

118 Cost-effectiveness analysis was performed to determine t

119 Cost-effectiveness analysis was performed to determine t

120 An incremental cost-effectiveness analysis was performed to determine w

121 An incremental cost-effectiveness analysis was performed to identify st

122 An incremental cost-effectiveness analysis was performed to identify tr

123 A cost-effectiveness analysis was performed using a Markov

124 A multi-institutional prospective cohort cost-effectiveness analysis was performed.

125 An incremental cost-effectiveness analysis was subsequently employed to

126 The primary end point for the cost-effectiveness analysis was the incremental cost per

127 Cost-effectiveness analysis was used to evaluate alterna

128 For a long-term cost-effectiveness analysis, we created a simulation mod

129 For this cost-effectiveness analysis, we used a transmission mode

130 " Second, it describes decision analysis and cost-effectiveness analysis, which are quantitative mode

131 A cost-effectiveness analysis will also be performed.

132 Cost-effectiveness analysis will continue to be the most

133 A cost-effectiveness analysis with therapy targeted to hig

134 We used a Markov model to do a cost-effectiveness analysis with two combination regimen